A Phase IIa Exploratory Study of CriPec® docetaxel Monotherapy in Subjects with Platinum Resistant Ovarian Cancer.
Phase of Trial: Phase II
Latest Information Update: 06 Dec 2019
Price : $35 *
At a glance
- Drugs Docetaxel (Primary)
- Indications Carcinoma; Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Therapeutic Use
- Acronyms CINOVA
- Sponsors Cristal Therapeutics
- 25 Oct 2018 According to a Cristal Therapeutics media release, first patient has been dosed.
- 12 Oct 2018 New trial record